Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2010 Q2- Text added to 2010 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
Coll freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
Coll freshman Avg
|
New words:
Abbott, AstraZeneca, attack, bilateral, binding, cell, chemical, chose, compatible, compliant, concomitant, concurrence, deducting, description, Eligard, embolism, Endo, FARESTON®also, FARESTON®or, FARESTON®will, feedback, Ferring, Firmagon, free, globulin, hypothalamic, incapable, input, lesser, lung, Lupron, meaningful, ofFARESTON®to, open, orchiectomy, prepaid, pursuit, renegotiate, renegotiation, resolve, satisfactorily, serum, sex, SHBG, stage, standard, suppressed, Trelstar, underwriter, underwriting, underwritten, viable, Watson, young, Zoladex
Removed:
absolute, acute, addressing, anabolic, Assessment, blind, blood, BMD, body, commenced, concept, demonstrating, density, detect, detrimental, diagnostic, dispute, effort, elderly, essential, higher, involuntary, lean, lipid, living, mineral, morphometric, notably, physical, progression, proof, randomized, reached, redemption, size, skeletal, SPA, statistically, subset, survival, synthesize, test, vertebral, weight
Valuein 2010 Q2 filing- Value in 2010 Q3 filing
Original filings
Filing view